Drug Profile

OPGx RHO

Alternative Names: IC-100 - IVERIC Bio; OPGx-RHO

Latest Information Update: 15 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Florida Research Foundation; University of Pennsylvania
Class Eye disorder therapies; Gene therapies
Mechanism of Action Gene transference; Rhodopsin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Retinitis pigmentosa

Most Recent Events

08 May 2026 Pharmacodynamics and adverse event data from preclinical trial in Retinitis pigmentosa released by Opus Genetics
06 Apr 2026 Opus Genetics expected to enter clinical development of OPGx RHO in the second half of 2027
12 Dec 2025 OPGx RHO is still in preclinical for Retinitis pigmentosa in the USA (Opus Genetics pipeline, December 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com